Lung Cancer
Conference Coverage
High-dose TRT: A new standard of care for LS-SCLC?
Though it conferred a significant improvement in survival without increasing toxicity, high-dose thoracic radiotherapy should not be the new...
Opinion
The scope of under- and overtreatment in older adults with cancer
News
Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise
Data suggest fewer people are dying from stomach cancer, but in some countries, the risk of colorectal cancer death is increasing or declining...
Conference Coverage
Lorlatinib: Another first-line option for ALK-positive NSCLC?
Lorlatinib bested crizotinib as first-line therapy for ALK-positive non–small cell lung cancer.
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Article
COVID-19 prompts ‘democratization’ of cancer trials
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.
News
First drug for MET+ NSCLC shows high response rates
Among patients with a MET exon 14 skipping mutation, capmatinib produced a response in 41% of previously treated patients and 68% of treatment-...
Article
Thromboembolic Events in Lung Cancer Patients Treated With Conventional Chemotherapy Alone Compared With Immunotherapy
Article
A Case of Alectinib Cutaneous Toxicity and Results of a Desensitization Protocol
News
Immunotherapy should not be withheld because of sex, age, or PS
